Cereno Scientific carries out directed share issue of SEK 100 million and secures loan financing of SEK 350 million

 MAQS Advokatbyrå has advised the biotechnology company Cereno Scientific in connection with a directed issue of new B-shares of SEK 100 million and a loan financing agreement securing financing of up to SEK 350 million.

 In addition to the directed share issue and the loan financing, the Board of Directors of Cereno Scientific has resolved to issue warrants which, if fully exercised, may provide the company with an additional SEK 215 million. 
Upon full exercise of both warrants and convertibles, the total financing amounts to SEK 665 million.

The purpose of the financing is to secure the financial runway for Cereno Scientific to reach its set milestones in the fourth quarter of 2027.

Cereno Scientific is an innovative biotechnology company pioneering treatments to enhance and extend the lives of people with rare cardiovascular diseases and pulmonary diseases. The company is listed on Nasdaq First North.

The MAQS team advising Cereno Scientific consisted primarily of Eric Ehrencrona, Fredrik Brusberg, Rebecka Malm, and Albin Davidsson Sirestål.